Across TCGA pan-cancer cohorts, LSP1P3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LSP1P3 data layer compared with 11 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LSP1P3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LSP1P3 expression acts as an unfavorable survival marker.
LUAD are the cancer types where LSP1P3 Mutation most reproducibly stratifies survival.